Bush's health care plan not most effective: study

[deadparrot]

Source: Reuters

WASHINGTON (Reuters) - At least two of the health care proposals being presented to Congress would cover all or nearly all of the Americans who lack health insurance, and many would lower spending, too, according to an independent report released on Monday.

Many of the plans would do more to cover uninsured Americans and lower costs than President George W. Bush's proposals, said the nonprofit Commonwealth Fund, which studies health care issues.

Health care has emerged as one of the top political issues of 2007, with groups as diverse as labor unions and major retailers teaming up to propose changes.

Several studies have found fault with the current U.S. system -- a free-for-all in which employers provide most health care, government programs provide much of the rest and 47 million Americans are left with no health insurance.

Read more: http://news.yahoo.com/s/nm/healthcare_congress_dc

[liberal N proud]

1. Rest assured, if bu$h is proposing a health care system, there is money in it for a crony

I am sure there is huge profit in what ever proposals bu$h would put on the table for his cronies at the cost of the patients and tax payers.

He has no other motive but to make money for the right wing.

[primavera]

2. It will probably involved imprisoning anyone...

... unable to pay 80% of their income on premiums.

[NashVegas]

3. Here's a Fun Little Detail

But the Commonwealth Fund analysis found that families with annual incomes of less than $10,000 would save only $23 in 2007, while families earning $150,000 or more per year would save an average of $1,263 under the Bush plan.

http://www.reuters.com/article/domesticNews/idUSN1919707420070319?pageNumber=2

[sakabatou]

4. He takes from the poor and gives to the rich...

[mcscajun]

5. *Bush's* health care plan is *very* effective.

It's the health care plan(s) for the rest of us that's totally fucked.

x(

[Vinca]

6. What health care plan???

It's a tax deduction for people who can afford to buy insurance.

[cosmicdot]

7. a link to the Commonwealth Fund report

a link to the Commonwealth Fund report (as written by http://www.lewin.com/ the Lewin Group, which is part of http://www.quintiles.com/ Quintiles Transnational Corporation, which merged with some entity called Pharma Services c. 2003, 4709 Creekstone Drive, Suite 200, Durham, North Carolina 27703-8411)

the report
http://www.cmwf.org/publications/publications_show.htm?doc_id=469753

http://www.cmwf.org/aboutus/aboutus_show.htm?doc_id=224817
http://www.qtrn.com/NewsEvents/Company+Milestones/2001+-+2006.htm


doesn't appear that they reviewed H.R. 676 - Library of Congress link
http://tinyurl.com/2cv797
Or, give your recipients confidence with a preview TinyURL:
http://preview.tinyurl.com/2cv797

"Quintiles companies have helped develop or commercialize every one of the world’s top 30 best-selling drugs."

>>> hard to know who is behind things or trending opinion in preferred directions <<<

2003 April

The Quintiles Board of Directors agrees to a merger with Pharma Services Holdings Inc., which will pay public shareholders $14.50 a share. Pharma Services was founded by Dennis Gillings, Ph.D., Chairman of the Board and founder of Quintiles, and One Equity Partners, LLC, the private equity arm of Bank One Corporation.

http://www.qtrn.com/NewsEvents/Company+Milestones/2001+-+2006.htm

from 2003 proxy

Merger Sub is a newly formed North Carolina corporation organized in connection with the merger and has not carried on any activities other than in connection with the merger. All of the outstanding capital stock of Merger Sub is owned by Pharma Services Intermediate Holding Corp., a wholly owned direct subsidiary of Pharma Services.

Pharma Services is a newly formed Delaware corporation organized in connection with the merger and has not carried on any activities other than in connection with the merger. Dennis B. Gillings, Ph.D. and Richard M. Cashin, Jr. are currently the sole directors of Pharma Services. Dr. Gillings is the Chairman of the board of directors and founder of Quintiles. Mr. Cashin is the Chairman of One Equity Partners LLC, an indirect subsidiary of Bank One Corporation. One Equity Partners LLC makes private equity investments.

~snip~

Merger Sub will merge with and into Quintiles, with Quintiles as the surviving corporation. After the merger, Quintiles will be an indirect wholly owned subsidiary of Pharma Services.

http://www.sec.gov/Archives/edgar/data/919623/000095014403010399/g82646ddef14a.htm

who, now, sits on Quintiles board? :shrug:
http://www.qtrn.com/NR/rdonlyres/3D4F340A-87C2-4367-9E74-95E6BE544F40/0/QTRNCompanyProfile.pdf

in 2002

Beneficial Owners (over 5% stock) were
----------------------------------- ------------ --------
Capital Group International, Inc.(1)........................ 11,358,350 9.6%
Capital Guardian Trust Company
11100 Santa Monica Blvd
Los Angeles, California 90025

Wellington Management Company, LLP(2)....................... 9,796,400 8.3%
75 State Street
Boston, MA 02109

Vanguard Specialized Funds
Vanguard Health Care Fund(3).............................. 7,308,200 6.2%
100 Vanguard Blvd
Malvern, PA 19355

OppenheimerFunds, Inc.(4)................................... 6,427,300 5.4%
498 Seventh Avenue
New York, NY 10018


Board of Directors in 2002
```````````````````````````


Robert C. Bishop, Ph.D. has served as a Director since April 1994. Since
June 1999, Dr. Bishop has served as Chairman of the Board and Chief Executive
Officer for AutoImmune Inc., a biotechnology company. From May 1992 to December
1999, Dr. Bishop served as President and Director of AutoImmune Inc. Dr. Bishop
serves as a director of Millipore Corporation, a multinational company that
applies its purification technology to research and manufacturing applications
in the biopharmaceutical industry; and serves as a Member of the Board of
Trustees/Managers for the MFS/Sun Life Series Trust and Compass Accounts at MFS
Investment Management and on the HealthCare/Life Sciences Board of Advisors for
One Equity Capital.

E. G. F. Brown has served as a Director since January 1998. Mr. Brown is
currently an independent director of Vantec Corporation, a Japanese logistics
business, Keller plc, a global construction company, and CH Jones, Ltd, a
holding company focused on Information Technology. His previous appointments
include Chairman -- Mainland Europe of Tibbett & Britten Group plc, an
international logistics service provider, Executive Director of T.D.G. plc, a
European logistics company, Operations Director of Exel plc, a global logistics
company and independent director of Datrontech PLC, a distributor of personal
computer components.

Vaughn D. Bryson has served as a Director since March 1997. Previously he
served as President and Chief Executive Officer of Eli Lilly and Company, a
pharmaceutical company, and also as a member of its Board of Directors.
Currently, Mr. Bryson is President of Life Science Advisors, LLC, a consulting
firm. Mr. Bryson is also President and founder of Clinical Products, Inc., a
medical foods company. Mr. Bryson is a director of Amylin Pharmaceuticals, Inc.,
Ariad Pharmaceuticals, Inc., AtheroGenics, Inc. and Chiron Corporation.

Chester W. Douglass, DMD, Ph.D. has served as a Director since 1983. Dr.
Douglass has served as Professor and Chairman of the Department of Oral Health
Policy and Epidemiology, Harvard University School of Dental Medicine and
Professor, Department of Epidemiology, Harvard University School of Public
Health since 1989. Previous to that time, Dr. Douglass served in academic
appointments in the School of Public Health and School of Dentistry at the
University of North Carolina at Chapel Hill from 1971-1978.

Dennis B. Gillings, Ph.D. founded the Company in 1982 and has served as
Chairman of the Board of Directors since its inception and as Chief Executive
Officer from its inception until April 2, 2001. Dr. Gillings serves as a
director of Triangle Pharmaceuticals, Inc., a company engaged in the development
of new drug candidates primarily in the antiviral area.

Jim D. Kever has served as a Director since June 1999. Mr. Kever currently
is a principal of Voyent Partners, LLC, a venture capital company. Between May
2000 and May 2001 he served as Co-Chief Executive Officer of Transaction
Services Division of WebMD Corporation, a healthcare transaction and information
service provider. Mr. Kever served as Chief Executive Officer of ENVOY
Corporation ("ENVOY"), a healthcare clearinghouse, from the Company's
acquisition of ENVOY in March 1999 as a wholly-owned subsidiary until its sale
in May 2000. Mr. Kever served as President and Co-Chief Executive Officer of
ENVOY from August 1995 until March 1999 and as a Director of ENVOY from its
incorporation in August 1994 until March 1999. Mr. Kever also is a director of
Transaction System Architects, Inc., a supplier of electronic payment software
products and network integration solutions and Tyson Foods, a food production
company, where he also serves on the audit and ethics committees.

Pamela J. Kirby, Ph.D., a Director nominee, became the Company's Chief
Executive Officer in April 2001. Previously, she served in Basel, Switzerland as
Head of Global Strategic Marketing and Business Development of the
Pharmaceuticals Division of F. Hoffmann-La Roche Ltd., a healthcare company. Dr.
Kirby served from 1996 until 1998 as global commercial director with British
Biotech plc, a drug development company. Dr. Kirby is a director of Smith &
Nephew plc.

Arthur M. Pappas has served as a Director since September 1994. Mr. Pappas
is Chairman and Chief Executive Officer of A. M. Pappas & Associates, LLC, an
international advisory services and investment company that works with life
science companies, products and related technologies. Mr. Pappas is a director
of Valentis Inc., a gene therapy research company; Embrex Inc., a research and
development company specializing in poultry in-the-egg delivery systems; and
AtheroGenics Inc., a biopharmaceutical company focused on research and
development of genes that regulate atherosclerosis and cancer.


William L. Roper, M.D., MPH, a Director nominee, has served as the dean of
the School of Public Health at the University of North Carolina at Chapel Hill,
professor of health policy and administration in the School of Public Health and
professor of pediatrics in the School of Medicine since July 1997. From August
1993 to July 1997, Dr. Roper served in a variety of capacities with the
Prudential Insurance Company of America, including Senior Vice President for
Medical Management. Dr. Roper is a director of Luminex Corporation, a research
and development company specializing in biological testing technologies with
applications throughout the life sciences industry, and DaVita Inc., a provider
of dialysis services for patients suffering from chronic kidney failure.

Eric J. Topol, M.D. has served as a Director since November 1997. In 2002,
Dr. Topol became the Provost and Chief Academic Officer of The Cleveland Clinic
Foundation, a health center, prior to which he was Chairman of the Department of
Cardiology and a co-Director of the Heart Center at The Cleveland Clinic
Foundation.

Virginia V. Weldon, M.D. has served as a Director since November 1997. Dr.
Weldon served as Senior Vice President, Public Policy, Monsanto Company, an
agro-chemicals and biotechnology (life sciences) company, from March 1989 until
her retirement in March 1998. Prior to 1989, Dr. Weldon was Professor of
Pediatrics and Deputy Vice Chancellor for Medical Affairs at Washington
University School of Medicine. Dr. Weldon also served as a Member of the Board
of GenAmerica Corporation, a mutual insurance company, which is now a subsidiary
of MetLife.

http://www.sec.gov/Archives/edgar/data/919623/000095014402002930/g74943def14a.txt


Further differentiating Quintiles' service delivery is its access to unique patient-level healthcare information and data products from Verispan, L.L.C., a joint venture co-founded by Quintiles and McKesson Corporation.

http://www.verispan.com/index.php - "This is certainly a time of transformational change for our industry – perhaps the most significant change since the late 1980s, when managed care influences were really beginning to shape the industry. Historically, clients have looked to Verispan to lead in times of uncertainty. We intend to stay ahead of the curve in this new era of change.

In January 2006, Medicare prescription drug coverage became a reality with the implementation of the government’s Medicare Modernization Act. We have already begun to see significant changes in the marketplace and are at the forefront of providing information and tools to help our clients quickly assess their particular situations, develop tailored solutions, and monitor their effectiveness. " - Verispan's CEO

"Verispan's clients include virtually all of the Top 50 pharmaceutical companies (market research, managed care, marketing/brand management, sales analytics, sales operations and other functions), most of the leading biotech and medical/surgical companies, the Food & Drug Administration (to track de-identified patient-centric utilization across the industry), Wall Street, consulting firms and other health care related organizations"

http://www.mckesson.com/en_us/McKesson.com/ - With McKesson's cutting-edge technology and software or their array of consultative services and training, you can optimize your claims management process.
(looks as if they're pegging on something other than a one-payer system)

McKesson Board of Directors
http://www.sec.gov/Archives/edgar/data/927653/000095013406011611/f21217adef14a.htm#109


5% + stockholders

Wellington Management Company, LLP

75 State Street
Boston, MA 02109 40,081,475 (1) 13.0 %
Legg Mason Funds Management, Inc.
Legg Mason Capital Management, Inc.
Legg Mason Focus Capital, Inc.
100 Light Street
Baltimore, MD 21202 26,183,840 (2) 8.5 %
Capital Research and Management Company

333 South Hope Street
Los Angeles, CA 90071 23,270,000 (3) 7.6 %
Vanguard Specialized Funds — Vanguard Health

Care Fund
100 Vanguard Boulevard
Malvern, PA 19355



~ just nosing around in the background ~
~~ never know what one might find ~~